1. Friesen KJ, Bugden SC. The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram. Drug Healthc Patient Saf. 2015;7:139–45.
https://doi.org/10.2147/DHPS.S91046
.
2. US Food and Drug Adminstration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Silver Spring, MD: US Food and Drug Adminstration; 2011.
http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm
.
3. US Food and Drug Adminstration. FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Silver Spring, MD: US Food and Drug Adminstration; 2012.
https://www.fda.gov/Drugs/DrugSafety/ucm297391.htm
.
4. Overø K, Hojelse F. The unexpected preclinical finding-elucidation of dog toxicity-citalopram. In Excerpts from a workshop on the use of pharmacology studies in drug safety assessment - present situation and future perspectives: September 26–27, Stockholm, Sweden. Stockholm: Association of the Swedish Pharmeceutical Industry (Lakemedelsindustriforen.) (LIF); Uppsala: Medical Products Agency [Lakemedelsverket]; 1994. p. 113–6.
5. Rohrbacher J, Bex P, Gallacher DJ. Citalopram metabolites inhibit IKs and IKr differentially: is this a possible explanation for the sudden deaths in dogs? J Pharmacol Toxicol Meth. 2012;66(2):170.
https://doi.org/10.1016/j.vascn.2012.08.040
.